Birmingham Alabama has a high rate of lung cancer. A high rate of smoking (about 23%) and high rates of pollution particularly soot pollution (according to the American Lung Association) are the primary causes.
Lung cancer is one of the most deadly forms of cancer and one of the most painful to treat.
An article published in The Lancet Oncology on October 22, 2011, offers hope for a longer life to lung cancer patients through the success seen in a Phase 2 trial of a cancer vaccine in Europe.
Elisabeth Quoix from Université de Strasbourg, Strasbourg, France, led the study.
The new cancer vaccine TG4010 enhances the effect of chemotherapy and slows down the progression of advanced non-small-cell-lung cancer (NSCLC), the most common type of lung cancer, compared with chemotherapy alone.
The TG4010 vaccine produces an immune response to the over expression of the protein MUC1 caused by lung cancer.
The vaccine produced a reduction in tumor progression and produced higher rates of tumor decrease in the majority of patients. The research also indicated a never before known biomarker to help identify patients likely to benefit from immunotherapy
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B
Elisabeth Quoix, Rodryg Ramlau, Virginie Westeel, Zsolt Papai, Anne Madroszyk, Alain Riviere, Piotr Koralewski, Jean-Luc Breton, Erich Stoelben, Denis Braun, Didier Debieuvre, Hervé Lena, Marc Buyse, Marie-Pierre Chenard, Bruce Acres, Gisèle Lacoste, Bérangère Bastien, Annette Tavernaro, Nadine Bizouarne, Jean-Yves Bonnefoy, Jean-Marc Limacher Hôpitaux Universitaires, Université de Strasbourg, Strasbourg, France (Prof E Quoix MD); Regional Center for Lung Disease, Wielkoposkie Centrum, Poznan, Poland (Prof R Ramlau MD); Hôpital Jean-Minjoz, Université de Franche-Comté, Besançon, France (Prof V Westeel MD); Pulmonologiai Osztály, Fejér Megyei Szent György Kórház, Székesfehérvár, Hungary (Z Papai MD); Institut Paoli-Calmettes, Marseille, France (A Madroszyk MD); Centre de Lutte Contre le Cancer François Baclesse, Caen, France (A Riviere MD); Szpital Specjalistyczny, Krakow, Poland (P Koralewski MD); Centre Hospitalier de Belfort-Montbéliard, Belfort, France (J-L Breton MD); Kliniken der Stadt Köln GmbH, Köln, Germany (E Stoelben MD); Centre Hospitalier de Briey, Briey, France (D Braun MD); Centre Hospitalier Intercommunal de Haute Saône, Vesoul, France (D Debieuvre MD); Hôpital Pontchaillou, Centre Hospitalier Universitaire, Rennes, France (H Lena MD); International Drug Development Institute, Louvain-la-Neuve, Belgium (M Buyse ScD); Hôpital de Hautepierre, Strasbourg, France (Prof M-P Chenard MD); and Transgene SA, Illkirch-Graffenstaden, France (B Acres PhD, G Lacoste MD, B Bastien MSc, A Tavernaro MSc, N Bizouarne PhD, J-Y Bonnefoy PhD, J-M Limacher MD)
The research was reviewed at the Eureka Alert web site on October 21, 2011.